Valeant Pharmaceuticals International Inc. is seeking to refinance the existing senior secured credit facilities of its wholly owned subsidiary Valeant Pharmaceuticals International. The $1.7 billion senior secured credit facility may comprise a $200 million revolving facility and a $1.5 billion term loan A facility, which includes a $500 million postponed draw term loan.
All parts will mature in 4.5 years. The facility, which is likely to close in October, is subject to market and other customary conditions. The existing loans are guaranteed by the multinational specialty pharmaceutical company.
Click here for the release from PR Newswire.